5-Amino-1MQ: The NNMT Inhibitor Behind the "Fat-Loss Peptide" Hype
5-Amino-1MQ is a small-molecule NNMT inhibitor with promising mouse and cell data for fat loss and muscle ageing — but zero human trials and no approval.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-07-02A small-molecule NNMT inhibitor with preclinical-only fat-loss and muscle-ageing signals; there are no human trials, no approval, and the realistic supply is unregulated research-chemical product.
Coherent NNMT-inhibition rationale acting on NAD+/methylation metabolism, though NNMT has dual, tissue-dependent roles.
Mouse obesity and aged-muscle studies plus rat pharmacokinetics, concentrated in a small research lineage.
No human clinical trials and effectively no human data.
The human-translation step has not been taken.
No human safety data; every inference is from short-term animal studies.
Preclinical-stage; no registered human programme.
Absent human evidence and single-lineage preclinical data keep confidence very low.
Not approved anywhere; sold as an unregulated research chemical of uncertain quality.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
An NNMT-inhibitor small molecule (not a peptide, despite being marketed as one). All published results are mechanistic, cell-culture or rodent; there are no human clinical trials and effectively no human data.
Safety snapshot
No human safety data exist; every inference is from short-term animal studies. NNMT has dual, tissue-dependent roles, and effects on one-carbon/NAD+/methylation metabolism — and any interaction with an undetected malignancy — are uncharacterised in people.
Regulatory & legality
Not approved by any regulator for any human use; sold as an unregulated research chemical of uncertain quality.
Where claims can exceed the evidence
The fat-loss and muscle-ageing story is preclinical only: encouraging animal signals do not establish human benefit. Commercial and community claims may extend beyond the evidence summarised here. This article does not provide dosing or protocol guidance.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
5-Amino-1MQ (5-amino-1-methylquinolinium, often shortened to 5-AMQ) is one of the most heavily marketed compounds in the metabolic and longevity space right now. It is sold online as an oral "fat-loss peptide" — which is the first thing worth correcting, because it is not a peptide at all. It is a synthetic small-molecule quinolinium salt designed to block a specific enzyme called NNMT.
The science behind the target is genuinely interesting, and the early animal work is consistent. But the honest headline is this: every published result on 5-Amino-1MQ comes from cell cultures, mice, or rats. There are no human clinical trials, no regulatory approval, and effectively zero human safety data. This is a compound with a compelling mechanistic story and an evidence base that stops at the laboratory bench.
This article walks through what it is, what the published research actually shows, and where the marketing has run well ahead of the data.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
AICAR: The Original "Exercise in a Pill" — What the Evidence Actually Shows
AICAR is the prototype AMPK-activating exercise mimetic. The endurance hype rests entirely on mice; the only positive human data are from heart surgery.
Epithalon (Epitalon): The Telomerase Peptide, Examined
A clear-eyed look at Epitalon, the pineal tetrapeptide pitched as a telomerase activator — what the evidence actually shows, and why it is weaker than the hype suggests.
MOTS-c: The Mitochondrial "Exercise Mimetic" Peptide — What the Evidence Actually Shows
A clear-eyed look at MOTS-c: strong mechanistic and rodent data for AMPK activation and insulin sensitivity, but human efficacy of the injected peptide is unproven.
NAD+ Boosting: What the Evidence Actually Shows
NAD+ precursors reliably raise blood NAD+ and are well tolerated, but human healthspan benefits stay unproven and IV NAD+ has essentially no outcome evidence.